Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Surviving heart failure: Robert L. Frye lecture.

¹University of California, San Francisco, USA.

Mayo Clinic Proceedings

|January 12, 2000

Summary

Heart failure is a growing concern with high mortality. Current treatments involve multiple medications, with ongoing research into novel therapies and prevention strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effects of different durations of pretreatment with losartan on myocardial infarct size, endothelial function, and vascular endothelial growth factor.

Journal of the renin-angiotensin-aldosterone system : JRAAS·2002

Same author

Secondhand tobacco smoke impairs rabbit pulmonary artery endothelium-dependent relaxation.

Chest·2001

Same author

Here today, ...

Journal of the American College of Cardiology·2001

Same author

Reflections on attending on the cardiology service.

Journal of the American College of Cardiology·2001

Same author

African American patients and heart disease.

Journal of the American College of Cardiology·2001

Same author

What is our contract with society?

Journal of the American College of Cardiology·2001

Area of Science:

Cardiology
Pharmacology

Background:

Heart failure incidence and prevalence are rising, leading to significant mortality.
Coronary artery disease is a primary cause in approximately two-thirds of heart failure cases.
Pathophysiology involves altered muscle function, hemodynamics, neurohormonal changes, and cellular mechanisms like apoptosis.

Discussion:

Standard therapy for symptomatic heart failure includes angiotensin-converting enzyme (ACE) inhibitors, digoxin, and diuretics.
Spironolactone is recommended for severe heart failure.
Large trials demonstrate mortality reduction with ACE inhibitors, spironolactone, and beta-blockers.

Key Insights:

Amiodarone is the preferred antiarrhythmic for symptomatic arrhythmias and aids in dilated cardiomyopathy.
Angiotensin II receptor blockers show promise compared to ACE inhibitors.
Polypharmacy represents the current standard of care for heart failure management.

Outlook:

Emerging treatments include endothelin and tumor necrosis factor antagonists.
A key future challenge is developing effective heart failure prevention strategies.

Related Experiment Videos